DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 087599
NDA 087599 describes NANDROLONE DECANOATE, which is a drug marketed by Abraxis Pharm, Akorn, Luitpold Pharms Inc, and Watson Labs, and is included in ten NDAs. Additional details are available on the NANDROLONE DECANOATE profile page.
The generic ingredient in NANDROLONE DECANOATE is nandrolone decanoate. There are fifteen drug master file entries for this compound. Additional details are available on the nandrolone decanoate profile page.
The generic ingredient in NANDROLONE DECANOATE is nandrolone decanoate. There are fifteen drug master file entries for this compound. Additional details are available on the nandrolone decanoate profile page.
Summary for 087599
| Tradename: | NANDROLONE DECANOATE |
| Applicant: | Watson Labs |
| Ingredient: | nandrolone decanoate |
| Patents: | 0 |
| Therapeutic Class: | Hormonal Agents, Stimulant/Replacement/Modifying (Sex Hormones/Modifiers) |
| Formulation / Manufacturing: | see details |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 100MG/ML | ||||
| Approval Date: | Oct 6, 1983 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
